Form 4: Patricia C Hirano, SVP at Soleno Therapeutics, Sells Shares to Cover Tax Obligations

Patricia C Hirano, Senior Vice President at Soleno Therapeutics, sold shares of common stock on July 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 1, 2024, Patricia C Hirano, a Senior Vice President at Soleno Therapeutics Inc. (SLNO), sold shares of the company's common stock.
• The sales were executed in two transactions to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The first transaction involved the sale of 473 shares at a weighted average price of $41.2217, with individual prices ranging from $40.39 to $41.38.
• The second transaction involved the sale of 1,697 shares at a weighted average price of $41.6254, with individual prices ranging from $41.39 to $42.08.
• Following these transactions, Hirano still beneficially owns 48,754 shares of Soleno Therapeutics Inc. common stock, some of which are RSUs representing a contingent right to receive one share of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales for tax purposes, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Insider sales to cover tax obligations on vesting RSUs are a common practice across publicly traded companies.
• The size of the transactions is relatively small compared to the overall market capitalization of Soleno Therapeutics, suggesting it is unlikely to have a significant impact on the stock price.
• Comparable companies in the biotechnology sector also regularly see Form 4 filings related to RSU vesting and tax obligation sales.

Stakeholder Impact

• The stock sales are unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates